Table 2.
Matched analysis comparing the Historical Control (HC) and the Prospective Cohort (PC)
| Variable | HC (N=150) | PC (N=75) | OR (95% CI) | p-value |
|---|---|---|---|---|
| Mean number of sex partners over the last year (SD) | 2.84 (4.08) | 2.57 (3.52) | 1.1 (0.9, 1.3) | NS |
| Mean number of sex partners last 2 months (SD) | 1.44 (1.22) | 1.19 (0.87) | 1.2 (0.9, 1.5) | NS |
| Mean instances of vaginal intercourse last 2 months (SD) | 4.72 (5.29) | 5.22 (11.2) | 1.0 (0.9, 1.2) | NS |
| Mean instances of vaginal intercourse without a condom last 2 months (SD) | 3.8 (11.1) | 1.8 (3.9) | 0.5 (0.4, 0.6) | 0.001 |
| Gonorrhea, N (%) | 6 (4%) | 0 (0%) | -- | -- |
| Chlamydia, N (%) | 17 (11.3) | 9 (12.0%) | 0.9 (.04, 2.2) | NS |
| Trichomonas, N (%) | 10 (6.7%) | 1 (1.3%) | 5.3 (0.7, 42.3) | NS |
| Any high risk HPV types, N (%) | 62 (41.3%) | 25 (36.0%) | 1.3 (0.7, 2.2) | NS |
| Any low risk HPV types, N (%) | 50 (33.3%) | 29 (28.7%) | 0.8 (.04, 1.4) | NS |
| HPV 6, 11, 16, 18; N (%)* | 34 (24.0%) | 4 (5.3%) 5.6 | (1.9, 16.5) | 0.002 |
| HPV 16 and 18, N (%) | 25 (16.7%) | 4 (5.3%) | 3.6 (1.2, 10.6) | 0.025 |
*
When prospective cohort was limited to the 59 who received ≥ 2 doses, the OR increases to 9.5 (CI =2.2, 41.6), p=0.03.